How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Bio-Rad Market
- By Product Type: Life Science Research Products, Clinical Diagnostics Instruments, Quality Control Products, Laboratory Equipment, Software and Informatics Solutions
- By End User: Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Healthcare Facilities, Industrial and Environmental Testing Labs
- By Technology: PCR and qPCR Systems, Electrophoresis and Blotting Systems, Chromatography Systems, Immunoassay Platforms, Mass Spectrometry Instruments
- By Application: Molecular Biology Research, Protein Analysis, Cell Biology, Clinical Diagnostics Testing, Food Safety and Environmental Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Life Science Research Products leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Bio-Rad Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
End User 5
Technology 5
Application 5
Companies profiled
Bio-Rad Laboratories
Thermo Fisher Scientific
Agilent Technologies
Danaher Corporation
PerkinElmer
QIAGEN
Merck KGaA (MilliporeSigma)
GE Healthcare Life Sciences (Cytiva)
Illumina
Bruker Corporation
Waters Corporation
Shimadzu Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Danaher Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PerkinElmer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →QIAGEN
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merck KGaA (MilliporeSigma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →GE Healthcare Life Sciences (Cytiva)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Illumina
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bruker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Waters Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Shimadzu Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Tecan Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Eppendorf
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BD Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$4,041M by 2033 · 7.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Life Science Research Products51.2
- Clinical Diagnostics Instruments16.9
- Quality Control Products17.2
- Laboratory Equipment6.7
- Software and Informatics Solutions8.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$771.6M → $1,185M · 5.5%
Europe$537.8M → $1,029M · 8.5%
Asia Pacific$491.0M → $818.9M · 6.6%
Latin America$304.0M → $507.6M · 6.6%
Middle East and Africa$233.8M → $421.0M · 7.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.022026
7.032027
7.052028
7.072029
7.082030
7.092031
7.112032
7.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bio-Rad Laboratories11.9
- Thermo Fisher Scientific17.4
- Agilent Technologies8.8
- Danaher Corporation9.8
- PerkinElmer8.5
- QIAGEN15.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type28.5%
End User28.9%
Technology10.5%
Application32.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.9
- Europe26.0
- Asia Pacific20.7
- Latin America12.8
- Middle East and Africa10.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | 78 | 77 | 90 | 78 | 85 | 86 | 82 |
| Thermo Fisher Scientific | 83 | 90 | 93 | 70 | 75 | 81 | 82 |
| Agilent Technologies | 78 | 86 | 85 | 66 | 82 | 68 | 78 |
| Danaher Corporation | 70 | 57 | 71 | 78 | 79 | 64 | 70 |
| PerkinElmer | 72 | 61 | 68 | 64 | 74 | 62 | 67 |
| QIAGEN | 67 | 65 | 48 | 58 | 70 | 68 | 63 |
| Merck KGaA (MilliporeSigma) | 54 | 60 | 50 | 58 | 46 | 56 | 54 |
| GE Healthcare Life Sciences (Cytiva) | 41 | 47 | 43 | 54 | 43 | 56 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bio-Rad Laboratories
- Thermo Fisher Scientific
- Agilent Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Thermo Fisher Scientific | ◐ | ✓ | ✓ | − | ◐ | ✓ |
| Agilent Technologies | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Danaher Corporation | ◐ | − | ✓ | ◐ | ✓ | ◐ |
| PerkinElmer | − | ◐ | ✓ | ◐ | − | ◐ |
| QIAGEN | ◐ | ◐ | − | ◐ | − | − |
| Merck KGaA (MilliporeSigma) | − | ◐ | − | − | − | − |
| GE Healthcare Life Sciences (Cytiva) | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bio-Rad Laboratories82
2Thermo Fisher Scientific82
3Agilent Technologies78
4Danaher Corporation70
5PerkinElmer67
6QIAGEN63
7Merck KGaA (MilliporeSigma)54
8GE Healthcare Life Sciences (Cytiva)47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Bio-Rad LaboratoriesThermo Fisher ScientificAgilent Technologies
Challenger2
Strong scale, closing on the leaders.
Danaher CorporationPerkinElmer
Contender1
Focused players with pockets of strength.
QIAGEN
Niche2
Specialists in a single segment or region.
Merck KGaA (MilliporeSigma)GE Healthcare Life Sciences (Cytiva)
Go-to-market strategy
Land Product Type in North America, then scale across Bio-Rad Market — a $116M beachhead inside a $1.71B market.
Beachhead (SOM)$116Mobtainable near-term
Serviceable (SAM)$628Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Life Science Research Products
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Clinical Diagnostics Instruments
Strong fit — clear ROI and a fast path to value.
End user64 fit
Quality Control Products
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Bio-Rad Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified23%
Evaluation15%
Closed-won7%
$19.5KCAC
$99KLTV
5.1:1LTV : CAC
< 5 moCAC payback
Investment thesis
Bio-Rad Market is a durable-growth opportunity — $2.26B by 2033, compounding at 8.7%.
TAM · 2025$1.16Btoday
TAM · 2033$2.26Bforecast
CAGR8.7%2027–2033
Cumulative$14.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.26BTotal addressable market
SAM$944MServiceable available market
SOM$199MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.7% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.26BLarge & growingTAM by 2033 at 8.7% CAGR
$944MServiceable nowreachable with today’s model
$199MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.76BBear5.7% CAGR
$2.26BBase8.7% CAGR
$2.90BBull11.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Bio-Rad Market — a $6.59B market by 2033. Plan: grow share from 8.5% to 16.6%.
Market size · 2033$6.59Btotal addressable
Market CAGR10.9%2027–2033
Target share16.6%from 8.5% today
Revenue ambition$1.09Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 16.6% | On track |
| Revenue | $529M | $1.09B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 32.1% | 44.8% | On track |
| Customer retention | 85.5% | 94.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $148M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Bio-Rad Market conversation — a $2.78B market you can size, segment and defend in minutes.
Market size · 2033$2.78Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,342+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 4 mopayback period
$89K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Bio-Rad LaboratoriesThermo Fisher ScientificAgilent TechnologiesDanaher CorporationPerkinElmerQIAGENMerck KGaA (MilliporeSigma)GE Healthcare Life Sciences (Cytiva)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Bio-Rad Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Bio-Rad Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Bioreactors & Fermenters Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBioremediation Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBioresorbable (Resorbable) Polymers Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportBio-Resorbable Ceramic Market
Market size, share, segmentation and regional forecast.
$407M market · 2025 base year
View reportBio-Resorbable Pins and Screw Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBioresorbable Polymer Market
Market size, share, segmentation and regional forecast.
$942M market · 2025 base year
View reportBIOS Firmware Technology Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBio-Safe Hand-Washing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBiosafety Testing Services for Biologics BPO Service Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBiosecurity Type Sterilizer Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBiosensor For Non-Clinical Applications Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBiosensors and Nanosensors Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.